Complementary roles of bone scintigraphy and MR imaging in the detection and long-term follow-up of primary non-Hodgkin’s bone lymphoma in a child-case report

详细信息    查看全文

• 作者：Vlajkovi? Marina ; Raji? Milena ; Petronijevi? Vesna ; Petrovi? Sla?ana…
• 关键词：Three ; phase bone scintigraphy ; Primary bone lymphoma ; MR imaging ; Children ; F ; 18 ; FDG PET/CT
• 刊名：Skeletal Radiology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：44
• 期：6
• 页码：863-868
• 全文大小：1,652 KB
• 参考文献：1.Glotzbecker MP, Kersun LS, Choi JK, Wills BP, Schaffer AA, Dormans JP. Primary non-Hodgkin’s lymphoma of bone in children. J Bone Joint Surg. 2006;88A:583-4.View Article
  2.Suryanarayan K, Shuster JJ, Donaldson SS, Hutchison RE, Murphy SB, Link MP. Treatment of localized primary non-Hodgkin’s lymphoma of bone in children: a pediatric oncology group study. J Clin Oncol. 1999;17:456-.PubMed
  3.Doll C, Wulff B, Rossler J, Schaper J, Havers W. Primary B-cell lymphoma of bone in children. Eur J Pediatr. 2001;160:239-2.View Article PubMed
  4.Roca-Bielsa I, Vlajkovic M. Pediatric nuclear medicine and pediatric radiology. Pediatr Radiol. 2013;43:391-.View Article PubMed
  5.Medina-Gálvez N, Pedraz T. Nuclear Medicine in Musculoskeletal Disorders: Clinical Approach. In: 12 Chapters on Nuclear Medicine. Croatia: InTech Europe; 2011.
  6.Costelloe CM, Chuang HH, Madewell JE. FDG PET/CT of primary bone tumors. AJR. 2014;202:521-1.View Article
  7.Ulaner GA, Magnan H, Healey JH, Weber WA, Meyers PA. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18?F-FDG PET/CT Is Performed? AJR. 2014;202:859-7.View Article PubMed
  8.Costelloe CM, Murphy WA, Chasen BA. Musculoskeletal pitfalls in 18?F-FDG PET/CT: pictorial review. AJR. 2009;193:1-3.View Article
  9.Mengiardi B, Honegger H, Hodler J, Exner UG, Csherhati MD, Brühlmann W. Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. AJR. 2005;184:185-2.View Article PubMed
  10.Franzius C, Sciuk J, Daldrup-Link H, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000;27:1305-1.View Article PubMed
  11.Israel O, Mekel M, Bar-Shalom R, Epelbaum R, Hermony N, Haim N, et al. Bone Lymphoma: 67?Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med. 2002;43:1295-03.PubMed
  12.Krishnan A, Shirkhoda A, Tehranzadeh J, Armin AR, Irwin R, Les K. Primary bone lymphoma: radiographic-MR imaging correlation. RadioGraphics. 2003;23:1371-7.View Article PubMed
  13.Menon N, Madhok R. Symmetrical polyarthritis is not always rheumatoid. Ann Rheum Dis. 1994;53:631-.View Article PubMed Central PubMed
  14.Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME, Kjeldsberg CR, et al. Non-Hodgkin’s lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a children’s cancer group report. J Clin Oncol. 2002;20:2293-01.View Article PubMed
  15.Zhang X, Chang CK, Song LX, Xu L, Wu LY, Li X. Primary lymphoma of bone: a case report and review of the literature. Med Oncol. 2011;28:202-.View Article PubMed
  16.Newman EN, Jones RL, Hawkins DS. An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma. Pediatr Blood Cancer. 2013;60:1113-.View Article PubMed
  17.Roca I, Barber I, Fontecha CG, Saldado F. Evaluation of bone viability. Pediatr Radiol 2013; 393-05.
  18.Palestro CJ, Torres MA. Radionuclide imaging of orthopedic infections. Semin Nucl Med. 1997;27:334-5.View Article PubMed
  19.Hicks DG, Gokan T, O’Keefe RJ, Totterman SM, Fultz PJ, Judkins AR, et al. Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. Cancer. 1995;75(4):973-0.View Article PubMed
  20.Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, et al. Coleman monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37:1438-44.PubMed
  
• 作者单位：Vlajkovi? Marina (1)
  Raji? Milena (1)
  Petronijevi? Vesna (2)
  Petrovi? Sla?ana (3)
  Artiko Vera (4)
  
  1. Center of Nucler Medicine, Clinical Center Ni?, Blvd dr Zorana ?in?i?a 48, 18000, Ni?, Serbia
  2. Clinic of Physical Medicine, Rehabilitation and Prosthetics, Clinical Center Ni?, Ni?, Serbia
  3. Center of Radiology, Clinical Center Ni?, Ni?, Serbia
  4. Center of Nuclear Medicine, Clinical Center of Serbia, Belgrade, Serbia
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Imaging and Radiology
  Orthopedics
  Pathology
  Nuclear Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2161

文摘

The aim of our report is to demonstrate the complementary roles of bone scintigraphy (BS), magnetic resonance imaging (MR), and positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose (F-18-FDG PET/CT) in the diagnosis and treatment monitoring of a child with primary non-Hodgkin’s lymphoma of bone (PLB). Increased blood flow, high tissue accumulation, and markedly increased uptake on the late BS pointed toward an active bone process in the left femoral region. Bone marrow infiltration of the left femur and cortical sclerosis, which were both demonstrated by MR imaging, were later confirmed as PLB by bone marrow biopsy. The normalizations of the flow and tissue phases of BS a year after treatment and during the entire follow-up were in keeping with inactive disease and clinical remission. However, even 8?years after treatment and complete remission, MR imaging demonstrated persistent unmodified bone marrow alteration and appreciable cortical involvement. A slightly increased metabolic activity of the left femoral epiphysis demonstrated by F-18-FDG PET/CT and mild activity in the same region on delayed BS were demonstrated in the late follow-up. Our results strongly suggest that BS and MR imaging should be included in the diagnostic algorithm of children with undefined bone symptoms. However, mild metabolic activity on the F-18-FDG PET/CT scan could not reliably differentiate between the presence or absence of disease in a patient with PLB in clinical remission.